MBX Biosciences, Inc. MBX Net proceeds from sales of subsidiary shares
Net proceeds from sales of subsidiary shares at other companies
Other financials
Where this comes from
Reported directly by MBX Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceInitialPublicOffering.
The official record: MBX Biosciences, Inc.’s 10-K, filed March 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about MBX Biosciences, Inc.'s net proceeds from sales of subsidiary shares.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is MBX Biosciences, Inc.'s net proceeds from sales of subsidiary shares?
- MBX Biosciences, Inc. (MBX) reported net proceeds from sales of subsidiary shares of $0 in Q4 2025.
- How has MBX Biosciences, Inc.'s net proceeds from sales of subsidiary shares changed year-over-year?
- MBX Biosciences, Inc.'s net proceeds from sales of subsidiary shares decreased by 100.0% year-over-year, from $43.64M to $0.
- What does net proceeds from sales of subsidiary shares mean?
- This captures the net cash proceeds generated specifically from the company's initial public offering of shares. It serves as a critical liquidity event for biopharmaceutical firms to transition from private funding to public market capital. This metric is essential for assessing the company's initial capitalization and ability to fund long-term clinical development programs.